TY  - JOUR
AU  - Spigel, David R
AU  - Edelman, Martin J
AU  - O'Byrne, Kenneth
AU  - Paz Ares, Luis Gonzaga
AU  - Mocci, Simonetta
AU  - Phan, See
AU  - Shames, David S
AU  - Smith, Dustin
AU  - Yu, Wei
AU  - Paton, Virginia E
AU  - Mok, Tony
PY  - 2017
DO  - 10.1200/JCO.2016.69.2160
SN  - 0732-183X
UR  - http://hdl.handle.net/20.500.12105/8385
AB  - Purpose The phase III OAM4971g study (METLung) examined the efficacy and safety of onartuzumab plus erlotinib in patients with locally advanced or metastatic non-small-cell lung cancer selected by MET immunohistochemistry whose disease had progressed...
LA  - eng
PB  - American Society of Clinical Oncology (ASCO)
KW  - Administration, Intravenous
KW  - Administration, Oral
KW  - Adult
KW  - Aged
TI  - Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung
TY  - journal article
ER  -